J. Goldman & CO LP Immuno Gen, Inc. Transaction History

J. Goldman & CO LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$2.41 - $5.91 $2.42 Million - $5.94 Million	-1,004,876 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $2.79 Million - $6.88 Million	708,763 Added 239.36%	1,004,876 $4.82 Million
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $2.55 Million - $3.33 Million	296,113 New	296,113 $2.8 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.